BeiGene, Ltd. (BGNE)
Largest Insider Buys in Sector
BGNE Stock Price History Chart
BGNE Stock Performance
About BeiGene, Ltd.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Activity of BeiGene, Ltd.
Over the last 12 months, insiders at BeiGene, Ltd. have bought $0 and sold $217.47M worth of BeiGene, Ltd. stock.
On average, over the past 5 years, insiders at BeiGene, Ltd. have bought $50M and sold $369.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 165,529 shares for transaction amount of $50M was made by AMGEN INC (10 percent owner) on 2021‑09‑10.
List of Insider Buy and Sell Transactions, BeiGene, Ltd.
| 2024-06-24 | Sale | Wu Xiaobin | President, COO & GM China | 1,459 0.0014% | $159.79 | $233,133 | -5.13% | |
| 2024-06-24 | Sale | Wang Lai | Global Head of R&D | 1,064 0.001% | $159.80 | $170,030 | -5.13% | |
| 2024-06-24 | Sale | Wang Julia Aijun | Chief Financial Officer | 899 0.0008% | $155.66 | $139,938 | -5.13% | |
| 2024-06-24 | Sale | OYLER JOHN | Chief Executive Officer | 2,789 0.0026% | $159.58 | $445,070 | -5.13% | |
| 2024-06-18 | Sale | Wu Xiaobin | President, COO & GM China | 2,627 0.0023% | $154.36 | $405,516 | +0.73% | |
| 2024-06-18 | Sale | Wang Lai | Global Head of R&D | 841 0.0007% | $153.75 | $129,305 | +0.73% | |
| 2024-06-17 | Sale | Wu Xiaobin | President, COO & GM China | 627 0.0006% | $159.00 | $99,692 | -2.41% | |
| 2024-06-17 | Sale | Wang Lai | Global Head of R&D | 1,500 0.0013% | $159.24 | $238,857 | -2.41% | |
| 2024-06-17 | Sale | Wang Julia Aijun | Chief Financial Officer | 916 0.0008% | $159.04 | $145,678 | -2.41% | |
| 2024-06-17 | Sale | OYLER JOHN | Chief Executive Officer | 1,281 0.0012% | $159.35 | $204,125 | -2.41% | |
| 2024-06-17 | Sale | Lee Chan Henry | SVP, General Counsel | 439 0.0004% | $159.35 | $69,955 | -2.41% | |
| 2024-04-11 | Sale | OYLER JOHN | Chief Executive Officer | 12,084 0.0106% | $146.73 | $1.77M | +7.06% | |
| 2024-04-10 | Sale | OYLER JOHN | Chief Executive Officer | 26,716 0.0251% | $148.89 | $3.98M | +4.38% | |
| 2024-04-09 | Sale | OYLER JOHN | Chief Executive Officer | 11,200 0.0102% | $153.94 | $1.72M | +1.39% | |
| 2024-03-13 | Sale | OYLER JOHN | Chief Executive Officer | 12,332 0.012% | $177.56 | $2.19M | -11.59% | |
| 2024-03-12 | Sale | OYLER JOHN | Chief Executive Officer | 37,668 0.0356% | $164.02 | $6.18M | -4.47% | |
| 2024-02-29 | Sale | Wang Julia Aijun | Chief Financial Officer | 397 0.0004% | $167.08 | $66,331 | -5.45% | |
| 2023-11-14 | Sale | BAKER BROS. ADVISORS LP | 1.1M 0.9291% | $180.50 | $198.55M | -19.92% | ||
| 2023-07-31 | Sale | Lee Chan Henry | SVP, General Counsel | 791 0.0008% | $216.26 | $171,059 | -20.43% | |
| 2023-07-03 | Sale | Wang Julia Aijun | Chief Financial Officer | 472 0.0004% | $179.55 | $84,747 | -3.85% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 877603 0.8352% | $146.44 | 5 | 3 | +24.57% | |
| Wang Lai | Global Head of R&D | 0 0% | $146.44 | 0 | 12 | |
| OYLER JOHN | Chief Executive Officer | 0 0% | $146.44 | 0 | 94 | |
| Wu Xiaobin | President, COO & GM China | 0 0% | $146.44 | 0 | 28 | |
| Lee Chan Henry | SVP, General Counsel | 0 0% | $146.44 | 0 | 2 | |
| Wang Julia Aijun | Chief Financial Officer | 0 0% | $146.44 | 0 | 10 | |
| HHLR ADVISORS, LTD. | 10 percent owner | 142888241 135.9855% | $146.44 | 0 | 5 | |
| Hillhouse Capital Management, Ltd. | 10 percent owner | 39726779 37.8076% | $146.44 | 1 | 0 | <0.0001% |
| AMGEN INC | 10 percent owner | 18943802 18.0286% | $146.44 | 1 | 0 | <0.0001% |
| Yuan RuiRong | Chief Medical Officer | 130000 0.1237% | $146.44 | 1 | 0 | <0.0001% |
| Malley Thomas | director | 30000 0.0286% | $146.44 | 1 | 0 | +25.31% |
| Li Ji | EVP and Gl. Head of Bus. Dev. | 0 0% | $146.44 | 0 | 1 | |
| Huang Jane | CMO, Hematology | 0 0% | $146.44 | 0 | 55 | |
| Liang Howard | CFO & Chief Strategy Officer | 0 0% | $146.44 | 1 | 16 | <0.0001% |
| Wang Xiaodong | director | 0 0% | $146.44 | 0 | 46 | |
| Peterson Amy C. | CMO, Immuno-oncology | 0 0% | $146.44 | 0 | 7 | |
| Glazer Donald W. | director | 0 0% | $146.44 | 0 | 14 | |
| Chen Timothy Yung-Cheng | director | 0 0% | $146.44 | 0 | 8 | |
| Sanders Corazon (Corsee) D. | director | 0 0% | $146.44 | 0 | 1 |
Institutional Investor Ownership
| Baker Bros Advisors LP | $1.65B | 0.78 | 10.57M | 0% | +$0 | 20.76 | |
| Capital International Investors | $1.1B | 0.52 | 7.06M | +11.48% | +$113.78M | 0.22 | |
| Hillhouse Capital Advisors Ltd | $809.62M | 0.38 | 5.18M | 0% | +$0 | 17.69 | |
| PRIMECAP Management Co | $782.24M | 0.37 | 5M | +0.27% | +$2.06M | 0.59 | |
| Baillie Gifford Co | $583.14M | 0.27 | 3.73M | -3.56% | -$21.54M | 0.45 | |
| Temasek Holdings | $471.39M | 0.22 | 3.01M | 0% | +$0 | 2.61 | |
| T. Rowe Price | $316.86M | 0.15 | 2.03M | +6.18% | +$18.44M | 0.04 | |
| Fidelity Investments | $262.81M | 0.12 | 1.68M | -2.37% | -$6.39M | 0.02 | |
| BlackRock | $148.36M | 0.07 | 948,667 | +10.97% | +$14.67M | <0.01 | |
| Capital Group International Inc Ca | $134.24M | 0.06 | 858,364 | +6% | +$7.6M | 1.81 | |
| Boxer Capital, LLC | $78.19M | 0.04 | 500,000 | 0% | +$0 | 3.91 | |
| Artal Group S A | $63.3M | 0.03 | 404,782 | +0.07% | +$47,229.78 | 0.34 | |
| Bank of America | $55.22M | 0.03 | 353,102 | +100.18% | +$27.64M | 0.01 | |
| Public Investment Fund | $55.42M | 0.03 | 354,385 | 0% | +$0 | 0.31 | |
| Baird Financial Group Inc | $39.23M | 0.02 | 250,867 | +52.1% | +$13.44M | 0.08 | |
| First Trust | $34.69M | 0.02 | 221,831 | +0.95% | +$326,855.10 | 0.04 | |
| Invesco | $32.24M | 0.02 | 206,158 | -56.68% | -$42.18M | 0.01 | |
| Capital Group Private Client Services Inc | $32.65M | 0.02 | 208,800 | +5.87% | +$1.81M | 0.34 | |
| Capital International Sarl | $30.02M | 0.01 | 191,942 | +8.85% | +$2.44M | 1 | |
| Soleus Capital Management, L.P. | $23.16M | 0.01 | 148,100 | New | +$23.16M | 0.22 | |
| Artisan Partners | $22.67M | 0.01 | 144,930 | New | +$22.67M | 0.03 | |
| Morgan Stanley | $19.2M | 0.01 | 122,778 | -23.76% | -$5.98M | <0.01 | |
| Marshall Wace | $16.33M | 0.01 | 104,415 | +53.78% | +$5.71M | 0.02 | |
| Td Asset Management Inc | $17.64M | 0.01 | 112,779 | +10.93% | +$1.74M | 0.02 | |
| Mitsubishi UFJ Trust and Banking Corporation | $14.86M | 0.01 | 95,034 | -9.32% | -$1.53M | 0.03 | |
| Edmond De Rothschild Holding S A | $14.53M | 0.01 | 92,890 | +13.29% | +$1.7M | 0.06 | |
| Royal Bank of Canada | $14.15M | 0.01 | 90,485 | +60.86% | +$5.35M | <0.01 | |
| Affinity Asset Advisors | $12.85M | 0.01 | 82,143 | New | +$12.85M | 2.28 | |
| Capital International Ltd Ca | $11.71M | 0.01 | 74,874 | +14.03% | +$1.44M | 0.56 | |
| VanEck | $13.72M | 0.01 | 87,761 | +6.13% | +$792,118.65 | 0.02 | |
| Wells Fargo | $13M | 0.01 | 83,125 | +69.52% | +$5.33M | <0.01 | |
| Legal & General | $11.96M | 0.01 | 76,563 | +2.24% | +$262,057.63 | <0.01 | |
| Schroder Investment Management Group | $11.55M | 0.01 | 73,861 | +481.58% | +$9.56M | 0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $10.26M | 0.01 | 65,616 | +96.67% | +$5.04M | 0.02 | |
| Envestnet Asset Management Inc | $10.13M | 0.01 | 64,786 | +31.24% | +$2.41M | <0.01 | |
| Squarepoint Ops LLC | $11M | 0.01 | 70,312 | +234.95% | +$7.71M | 0.04 | |
| AXA | $8.36M | <0.01 | 53,467 | -3.02% | -$260,702.13 | 0.03 | |
| Goldman Sachs | $9.13M | <0.01 | 58,385 | -72.76% | -$24.39M | <0.01 | |
| Tang Capital Management, LLC | $5.79M | <0.01 | 37,000 | -56.47% | -$7.51M | 0.02 | |
| The Manufacturers Life Insurance Company | $7.25M | <0.01 | 46,347 | +16.57% | +$1.03M | 0.01 | |
| HSBC | $5.97M | <0.01 | 38,194 | +20.19% | +$1M | <0.01 | |
| Macquarie Group | $7.14M | <0.01 | 45,668 | +55.14% | +$2.54M | 0.01 | |
| Geode Capital Management | $5.64M | <0.01 | 36,075 | +0.98% | +$54,736.50 | <0.01 | |
| Integral Health Asset Management Llc | $6.26M | <0.01 | 40,000 | New | +$6.26M | 0.62 | |
| Bellevue Group | $3.9M | <0.01 | 24,929 | -12.84% | -$574,107.64 | 0.06 | |
| UBS | $4.48M | <0.01 | 28,647 | +281.4% | +$3.31M | <0.01 | |
| Barings LLC | $4.86M | <0.01 | 31,100 | -48.49% | -$4.58M | 0.13 | |
| Nan Fung Group | $3.6M | <0.01 | 23,022 | +91.5% | +$1.72M | 3.91 | |
| SEI Investments Company | $3.66M | <0.01 | 23,400 | -60.6% | -$5.63M | 0.01 | |
| Raymond James Associates | $3.32M | <0.01 | 21,199 | +68.29% | +$1.35M | <0.01 |